These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38018603)

  • 41. Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.
    Dieffenbach PB; Haeger CM; Coronata AMF; Choi KM; Varelas X; Tschumperlin DJ; Fredenburgh LE
    Am J Physiol Lung Cell Mol Physiol; 2017 Sep; 313(3):L628-L647. PubMed ID: 28642262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BMP6/TAZ-Hippo signaling modulates angiogenesis and endothelial cell response to VEGF.
    Pulkkinen HH; Kiema M; Lappalainen JP; Toropainen A; Beter M; Tirronen A; Holappa L; Niskanen H; Kaikkonen MU; Ylä-Herttuala S; Laakkonen JP
    Angiogenesis; 2021 Feb; 24(1):129-144. PubMed ID: 33021694
    [TBL] [Abstract][Full Text] [Related]  

  • 43. YAP/TAZ regulates sprouting angiogenesis and vascular barrier maturation.
    Kim J; Kim YH; Kim J; Park DY; Bae H; Lee DH; Kim KH; Hong SP; Jang SP; Kubota Y; Kwon YG; Lim DS; Koh GY
    J Clin Invest; 2017 Sep; 127(9):3441-3461. PubMed ID: 28805663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hippo signaling pathway and respiratory diseases.
    Tang W; Li M; Yangzhong X; Zhang X; Zu A; Hou Y; Li L; Sun S
    Cell Death Discov; 2022 Apr; 8(1):213. PubMed ID: 35443749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Angiotensin-converting enzyme 2 activation suppresses pulmonary vascular remodeling by inducing apoptosis through the Hippo signaling pathway in rats with pulmonary arterial hypertension.
    Yan D; Li G; Zhang Y; Liu Y
    Clin Exp Hypertens; 2019; 41(6):589-598. PubMed ID: 30806090
    [No Abstract]   [Full Text] [Related]  

  • 46. Common and Distinctive Functions of the Hippo Effectors Taz and Yap in Skeletal Muscle Stem Cell Function.
    Sun C; De Mello V; Mohamed A; Ortuste Quiroga HP; Garcia-Munoz A; Al Bloshi A; Tremblay AM; von Kriegsheim A; Collie-Duguid E; Vargesson N; Matallanas D; Wackerhage H; Zammit PS
    Stem Cells; 2017 Aug; 35(8):1958-1972. PubMed ID: 28589555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MST1/2 in PDGFRα
    An Y; Ren Y; Wang J; Zang J; Gao M; Wang H; Wang S; Dong Y
    Am J Physiol Renal Physiol; 2022 May; 322(5):F512-F526. PubMed ID: 35253468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-canonical IKB kinases regulate YAP/TAZ and pathological vascular remodeling behaviors in pulmonary artery smooth muscle cells.
    Aravamudhan A; Dieffenbach PB; Choi KM; Link PA; Meridew JA; Haak AJ; Fredenburgh LE; Tschumperlin DJ
    Physiol Rep; 2024 Apr; 12(7):e15999. PubMed ID: 38610069
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
    Budel SJ; Penning MM; Penning LC
    Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Control of skeletal morphogenesis by the Hippo-YAP/TAZ pathway.
    Vanyai HK; Prin F; Guillermin O; Marzook B; Boeing S; Howson A; Saunders RE; Snoeks T; Howell M; Mohun TJ; Thompson B
    Development; 2020 Nov; 147(21):. PubMed ID: 32994166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel role of Hippo-Yap/TAZ signaling pathway in lymphatic vascular development.
    Cha B; Moon S; Kim W
    BMB Rep; 2021 Jun; 54(6):285-294. PubMed ID: 33691907
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype.
    Anorga S; Overstreet JM; Falke LL; Tang J; Goldschmeding RG; Higgins PJ; Samarakoon R
    FASEB J; 2018 May; 32(5):2644-2657. PubMed ID: 29298862
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Hippo Pathway in Prostate Cancer.
    Salem O; Hansen CG
    Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Hippo signaling pathway provides novel anti-cancer drug targets.
    Bae JS; Kim SM; Lee H
    Oncotarget; 2017 Feb; 8(9):16084-16098. PubMed ID: 28035075
    [TBL] [Abstract][Full Text] [Related]  

  • 55. YAP/TAZ Are Mechanoregulators of TGF-
    Szeto SG; Narimatsu M; Lu M; He X; Sidiqi AM; Tolosa MF; Chan L; De Freitas K; Bialik JF; Majumder S; Boo S; Hinz B; Dan Q; Advani A; John R; Wrana JL; Kapus A; Yuen DA
    J Am Soc Nephrol; 2016 Oct; 27(10):3117-3128. PubMed ID: 26961347
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases.
    Yu Y; Su X; Qin Q; Hou Y; Zhang X; Zhang H; Jia M; Chen Y
    Pharmacol Res; 2020 Sep; 159():105009. PubMed ID: 32553712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.
    Elaimy AL; Amante JJ; Zhu LJ; Wang M; Walmsley CS; FitzGerald TJ; Goel HL; Mercurio AM
    Proc Natl Acad Sci U S A; 2019 Jul; 116(28):14174-14180. PubMed ID: 31235595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent YAP/TAZ and SMAD signaling mediate vocal fold fibrosis.
    Nakamura R; Hiwatashi N; Bing R; Doyle CP; Branski RC
    Sci Rep; 2021 Jun; 11(1):13484. PubMed ID: 34188130
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
    Juan WC; Hong W
    Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation.
    Pefani DE; Pankova D; Abraham AG; Grawenda AM; Vlahov N; Scrace S; O' Neill E
    Mol Cell; 2016 Jul; 63(1):156-66. PubMed ID: 27292796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.